ICON Releases NONMEM 7.2
ICON
announced the release of a new version of NONMEM, ICON’s non-linear, mixed effects modeling tool for Population Pharmacokinetic/Pharmacodynamic (PK/PD) data analysis.
One year following the release of NONMEM® 7, which included a new suite of statistical methods to support more complex models for analysing Population PK/PD data and a more comprehensive range of classical estimation methods, ICON has released NONMEM® 7.2, which includes the following enhancements:
- Parallel computing of a single problem over multiple cores or computers, significantly reducing completion time.
- Dynamic memory allocation according to problem size, eliminating the need to recompile the NONMEM® program for unusually large problems. User may override program generated suggested values using a statement in the control stream.
- Other improvements include control stream files that may be written in mixed case, added flexibility in the input and output of variance matrix parameters, XML markup version of the NONMEM® report file, as well as features to facilitate stochastic differential equations (SDE).
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
